García-Perdomo Herney Andrés, Dávila-Raigoza Angélica María, Korkes Fernando
Division of Urology/Urooncology, Department of Surgery, School of Medicine, Universidad del Valle, Cali, Colombia.
UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia.
Asian J Urol. 2024 Apr;11(2):221-241. doi: 10.1016/j.ajur.2022.11.005. Epub 2023 Sep 12.
Metabolomics has been extensively utilized in bladder cancer (BCa) research, employing mass spectrometry and nuclear magnetic resonance spectroscopy to compare various variables (tissues, serum, blood, and urine). This study aimed to identify potential biomarkers for early BCa diagnosis.
A search strategy was designed to identify clinical trials, descriptive and analytical observational studies from databases such as Medline, Embase, Cochrane Central Register of Controlled Trials, and Latin American and Caribbean Literature in Health Sciences. Inclusion criteria comprised studies involving BCa tissue, serum, blood, or urine profiling using widely adopted metabolomics techniques like mass spectrometry and nuclear magnetic resonance. Primary outcomes included description of metabolites and metabolomics profiling in BCa patients and the association of metabolites and metabolomics profiling with BCa diagnosis compared to control patients. The risk of bias was assessed using the Quality Assessment of Studies of Diagnostic Accuracy.
The search strategy yielded 2832 studies, of which 30 case-control studies were included. Urine was predominantly used as the primary sample for metabolite identification. Risk of bias was often unclear inpatient selection, blinding of the index test, and reference standard assessment, but no applicability concerns were observed. Metabolites and metabolomics profiles associated with BCa diagnosis were identified in glucose, amino acids, nucleotides, lipids, and aldehydes metabolism.
The identified metabolites in urine included citric acid, valine, tryptophan, taurine, aspartic acid, uridine, ribose, phosphocholine, and carnitine. Tissue samples exhibited elevated levels of lactic acid, amino acids, and lipids. Consistent findings across tissue, urine, and serum samples revealed downregulation of citric acid and upregulation of lactic acid, valine, tryptophan, taurine, glutamine, aspartic acid, uridine, ribose, and phosphocholine.
代谢组学已广泛应用于膀胱癌(BCa)研究,采用质谱和核磁共振光谱来比较各种变量(组织、血清、血液和尿液)。本研究旨在确定早期BCa诊断的潜在生物标志物。
设计检索策略,以识别来自Medline、Embase、Cochrane对照试验中央登记册以及拉丁美洲和加勒比卫生科学文献等数据库中的临床试验、描述性和分析性观察性研究。纳入标准包括使用质谱和核磁共振等广泛采用的代谢组学技术对BCa组织、血清、血液或尿液进行分析的研究。主要结果包括描述BCa患者的代谢物和代谢组学分析,以及与对照患者相比,代谢物和代谢组学分析与BCa诊断的关联。使用诊断准确性研究的质量评估来评估偏倚风险。
检索策略产生了2832项研究,其中包括30项病例对照研究。尿液主要用作代谢物鉴定的主要样本。在患者选择、指标测试的盲法和参考标准评估方面,偏倚风险通常不明确,但未观察到适用性问题。在葡萄糖、氨基酸、核苷酸、脂质和醛类代谢中鉴定出与BCa诊断相关的代谢物和代谢组学特征。
在尿液中鉴定出的代谢物包括柠檬酸、缬氨酸、色氨酸、牛磺酸、天冬氨酸、尿苷、核糖、磷酸胆碱和肉碱。组织样本中乳酸、氨基酸和脂质水平升高。在组织、尿液和血清样本中的一致发现显示柠檬酸下调,乳酸、缬氨酸、色氨酸、牛磺酸、谷氨酰胺、天冬氨酸、尿苷、核糖和磷酸胆碱上调。